Voyager Therapeutics, Inc. (NASDAQ:VYGR) Major Shareholder Ecor1 Capital, Llc Sells 456,000 Shares of Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) major shareholder Ecor1 Capital, Llc sold 456,000 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, January 9th. The shares were sold at an average price of $7.67, for a total transaction of $3,497,520.00. Following the sale, the insider now owns 4,297,907 shares of the company’s stock, valued at $32,964,946.69. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 11th, Ecor1 Capital, Llc sold 110,000 shares of Voyager Therapeutics stock. The shares were sold at an average price of $8.50, for a total transaction of $935,000.00.

Voyager Therapeutics Trading Up 12.6 %

Shares of NASDAQ VYGR opened at $8.95 on Thursday. The company has a 50 day simple moving average of $5.85 and a two-hundred day simple moving average of $6.09. Voyager Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $10.60. The stock has a market cap of $345.53 million, a price-to-earnings ratio of -19.46 and a beta of 0.93.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th.

Hedge Funds Weigh In On Voyager Therapeutics

Several large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Voyager Therapeutics by 1.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 843,711 shares of the company’s stock valued at $4,996,000 after purchasing an additional 15,761 shares during the period. Marshall Wace LLP acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $1,123,000. BlackRock Inc. increased its holdings in Voyager Therapeutics by 4.7% in the 3rd quarter. BlackRock Inc. now owns 590,504 shares of the company’s stock worth $3,496,000 after acquiring an additional 26,289 shares in the last quarter. Armistice Capital LLC increased its holdings in Voyager Therapeutics by 32.4% in the 3rd quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock worth $20,104,000 after acquiring an additional 832,000 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in Voyager Therapeutics by 1,746.8% in the 3rd quarter. Royal Bank of Canada now owns 12,004 shares of the company’s stock worth $71,000 after acquiring an additional 11,354 shares in the last quarter. 59.58% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

(Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.